In the evolving landscape of modern medicine, drug-device combination products—such as pre-filled syringes, drug-eluting stents, transdermal patches, and inhalers with integrated drug delivery systems—are increasingly common. These products merge a drug component with a medical device, creating a therapeutic solution that is often more effective than either component alone. However, a critical regulatory question persists: should such products be regulated as drugs, devices, or something in between? A growing consensus among regulators, pharmaceutical companies, and patient safety advocates argues that, in many cases, these combination products should be regulated primarily as drugs.
The primary justification for drug-based regulation lies in the nature of the product's primary mode of action (PMOA). According to the U.S. Food and Drug Administration (FDA), the PMOA determines which center will lead the review. If the primary therapeutic effect arises from the drug component—such as a biologic or chemical agent—the product is classified as a drug. For example, a drug-eluting stent releases an immunosuppressive or antiproliferative drug to prevent restenosis. The device provides structural support, but the drug's action is central to patient outcomes. Regulating such a product under the drug framework ensures rigorous evaluation of pharmacokinetics, toxicology, clinical efficacy, and manufacturing quality specific to pharmaceutical standards.
Regulating combination products as drugs offers several advantages. First, it mandates compliance with Good Manufacturing Practices (GMP) for drugs, which are more stringent than those for devices—covering sterile processing, stability testing, and impurity control. For products like pre-filled syringes or transdermal patches, even minor deviations in drug concentration or release kinetics can lead to serious adverse events. Drug-focused oversight ensures that these risks are minimized through robust quality control.
Second, drug regulation enforces comprehensive clinical trial requirements. Unlike most medical devices, which may only need to demonstrate safety and performance equivalence, drug-device combination products often require Phase I, II, and III trials to establish safety, dosing, and effectiveness. This is essential when the drug component is novel or has systemic effects. For instance, a combination inhaler containing a new bronchodilator must prove its pharmacological profile, drug-device interaction, and delivery reliability under real-world conditions.
Third, post-market surveillance obligations for drugs are more demanding. Reporting adverse events, conducting periodic safety updates, and managing risk with Risk Evaluation and Mitigation Strategies (REMS) are standard for drugs but not always for devices. Given that many combination products involve chronic use or direct patient self-administration, robust pharmacovigilance is necessary.
Some argue that device-based regulation is less burdensome and promotes faster market access. However, this approach may compromise patient safety and product reliability. A case in point: pre-filled syringes that experienced drug leakage or dose inaccuracy due to insufficient device testing during drug-focused review. Had the product been regulated solely as a device, these drug-related failures might have been overlooked.
The FDA's Office of Combination Products (OCP) provides assignment decisions and guidance to ensure clear regulatory pathways. In recent years, the trend has leaned toward drug-focused regulation for products where the drug component drives the therapeutic intent. This approach aligns with global regulatory frameworks, including the European Medicines Agency (EMA), which similarly classifies products based on their principal mode of action.
In conclusion, regulating drug-device combination products as drugs is not merely a bureaucratic preference—it is a patient-centered necessity. It ensures rigorous preclinical and clinical evaluation, high-quality manufacturing, and continuous post-market oversight. As innovation continues to blur the line between treatment and delivery technology, maintaining drug-based regulation for these integrated products will be key to safeguarding efficacy, safety, and public trust. Companies developing such products should proactively engage with regulators early, adopt drug-focused development strategies, and invest in multidisciplinary teams that bridge pharmaceutical science and device engineering. Only then can we fully harness the potential of combination products while upholding the highest standards of patient care.